The TCT 2024 Career Achievement Award will be presented to Robert A. Harrington, MD, during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientif
The TCT 2024 Career Achievement Award will be presented to Robert A. Harrington, MD, during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientif
Credit Adobe Stock
Promoted in April as the first large-scale drug study on the effectiveness of hydroxychloroquine to protect against COVID-19, the Detroit-based clinical trial has quietly been iced.
Henry Ford Health System officials told Bridge Michigan they could not find enough participants to continue studying whether the drug could help beat back the deadly pandemic.
Hydroxychloroquine an antimalarial drug that has also proven useful in treating rheumatoid arthritis, lupus, and other inflammatory diseases briefly produced some excitement last spring when it was promoted as a potential game-changer by President Trump. But early optimism gave way to broader medical studies, with the nation’s top health agencies eventually determining it was not effective in treating or preventing the spread of the novel coronavirus.